GVAG
AZN icon

Great Valley Advisor Group’s AstraZeneca AZN Stock Holding History

Great Valley Advisor Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$576K Buy
3,036
+18
+0.6% +$3.39K 0.01% 677
2026
Q1 		$595K Buy
3,018
+151
+5% +$29.1K 0.01% 630
2025
Q4 		$527K Buy
2,867
+345
+14% +$60.5K 0.01% 609
2025
Q3 		$386K Buy
2,522
+47
+2% +$7.11K 0.01% 700
2025
Q2 		$346K Buy
2,475
+479
+24% +$67.1K 0.01% 708
2025
Q1 		$293K Sell
1,996
-41
-2% -$5.93K 0.01% 732
2024
Q4 		$267K Sell
2,037
-27
-1% -$3.78K 0.01% 724
2024
Q3 		$321K Sell
2,064
-85
-4% -$13.7K 0.01% 673
2024
Q2 		$335K Sell
2,149
-144
-6% -$21.7K 0.01% 618
2024
Q1 		$310K Buy
2,293
+374
+19% +$49.5K 0.01% 601
2023
Q4 		$259K Sell
1,919
-237
-11% -$30.8K 0.01% 615
2023
Q3 		$292K Buy
2,156
+418
+24% +$57.1K 0.01% 553
2023
Q2 		$249K Buy
1,738
+37
+2% +$5.44K 0.01% 612
2023
Q1 		$236K Sell
1,701
-258
-13% -$34.7K 0.01% 609
2022
Q4 		$265K Buy
+1,959
New +$246K 0.01% 576
2022
Q3 		– Sell
-1,624
Closed -$215K – 677
2022
Q2 		$215K Buy
+1,624
New +$213K 0.01% 619
2021
Q4 		– Sell
-2,134
Closed -$256K – 598
2021
Q3 		$256K Sell
2,134
-840
-28% -$97.8K 0.02% 503
2021
Q2 		$339K Buy
2,974
+23
+0.8% +$2.52K 0.03% 427
2021
Q1 		$293K Sell
2,951
-11,681
-80% -$1.17M 0.03% 410
2020
Q4 		$1.46M Buy
14,632
+499
+4% +$52.9K 0.15% 151
2020
Q3 		$1.55M Buy
+14,133
New +$1.57M 0.19% 115

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Great Valley Advisor Group's AZN Position: Q2 2026 in Review

Great Valley Advisor Group increased its AstraZeneca (AZN) stake by 0.6% in Q2 2026, buying an estimated $3.39K and bringing the position to 3,036 shares worth $576K. The position accounts for 0.01% of the portfolio, ranked #677.

Great Valley Advisor Group first reported a position in AZN in Q3 2020 and has held it in 21 quarters since. The position peaked at $1.55M in Q3 2020. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Great Valley Advisor Group held 3,036 shares of AstraZeneca worth $576K as of Q2 2026.
  • Great Valley Advisor Group bought 18 AstraZeneca shares in Q2 2026, an estimated $3.39K.
  • AstraZeneca made up 0.01% of Great Valley Advisor Group's portfolio in Q2 2026, its #677 holding.
  • Great Valley Advisor Group first reported a position in AstraZeneca in Q3 2020 and has held it in 21 quarters since.
  • Great Valley Advisor Group's AstraZeneca position peaked at $1.55M in Q3 2020.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Great Valley Advisor Group's 13F filing for Q2 2026, filed 10 Aug 2026.